MedTrace Logo

Efficacy and Safety of Hizikia Fusiformis Extract in Subjects Showing Erosive Gastritis

NCT01689701 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2019-09-20

Study results available
· View outcomes & findings →

Summary

The investigators performed a double-blind parallel study in a group of Subjects Showing Erosive Gastritis who were given Hizikia Fusiformis Extract over a period of 4 weeks. Endoscopic observations were performed before and 4 weeks after the treatment, and the cure and improvement rates were investigated.

Conditions

  • Erosive Gastritis

Interventions

DIETARY_SUPPLEMENT

Hizikia Fusiformis extract

Hizikia Fusiformis extract(1.3g/d)

DIETARY_SUPPLEMENT

Placebo

Placebo(1.3g/d)

Sponsors & Collaborators

  • Chonbuk National University Hospital

    lead OTHER

Principal Investigators

  • Sang-Wook Kim, MD · Chonbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2011-08-31
Completion
2012-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01689701 on ClinicalTrials.gov